Cardi B broke out with “Bodak Yellow” almost a year before she released “Invasion of Privacy” in April 2018. Times critic ...

(UroToday.com) In the Rapid Abstract Session on the first day of the American Society for Clinical Oncology (ASCO) Genitourinary Cancer Symposium 2022, Dr. Gao presented results of a phase 1/2 study ...

With regards to safety and tolerability – in the phase 1a, evaluating increasing doses of SHR-1501 alone (200, 400, and 600 µg), and phase 1b part of SHR-1501 + BCG, no DLTs were observed, and the MTD ...

In zone 1, you’re warming up for a run, and in zone 5, you’re at an all-out sprint. Recently, zone 2 has gained MVP status among the five zones, thanks in part to longevity gurus like Peter ...

Ironheart's release has been long overdue.Originally conceived as a movie, the Marvel Phase 5 project was turned into a TV production in December 2020 – a developmental shift that came almost ...

MAIA has announced the trial design for an expansion of its THIO-101 pivotal Phase 2 trial in NSCLC to assess overall response rates (ORR) in advanced NSCLC patients receiving third line ...

Claudin-18 isoform 2 (CLDN18.2) has emerged as a promising therapeutic target in gastric or gastro-oesophageal junction cancer. Satricabtagene autoleucel (satri-cel; also known as CT041), an ...

Nintendo is counting on the Switch 2 to boost sagging sales.In the U.S., a chaotic pre-order process in April left some fans frustrated after the consoles quickly sold out.In Japan, the new ...

open-label Phase 1/2 multiple-ascending dose (MAD) clinical trial of DT-216P2. The RESTORE-FA trial is designed to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics ...

Background: While anti-PD-1 and anti-CTLA4 immunotherapies have efficacy in the treatment of patients (pts) with asymptomatic melanoma brain metastases (MBM), their efficacy in pts with symptomatic ...

Pioneering small-molecule program, NT-0796, targets chronic inflammation and its fundamental role in the complex cycle of weight regulation Oral, brain-penetrant NLRP3 inflammasome inhibitor being ...